TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for RET V804M resistance mutation drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Mutant Antigen (V804M) | RET V804M Kinase Domain Recombinant Protein. High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. Theoretical MW confirmed by SDS-PAGE. | View RET V804M Products |
| Wild-type Control | RET WT Kinase Domain Protein. For selectivity counter-screening against gatekeeper mutation. | View RET Products |
| Gene Delivery | RET V804M Lentivirus Particles. Full-length ORF with V804M mutation. HEK293 expressed, endotoxin controlled. For stable cell line construction (Ba/F3, NIH3T3, HEK293). | View RET V804M Products |
| Benchmark Ab | Anti-RET Recombinant Antibody. Positive control for target engagement and expression validation. | View RET V804M Products |
| Validator | RET siRNA Set. For knockdown verification and assay specificity controls. | View RET Products |
| Related Target A (Mutant) | RET M918T. Common oncogenic driver mutation for cross-screening. | View RET M918T Products |
| Related Target B (Fusion Partner) | KIF5B. Common RET fusion partner in NSCLC (KIF5B-RET). For fusion context studies. | View KIF5B Products |
| Related Target C (Bypass) | MET (c-Met). Bypass resistance pathway and parallel RTK in NSCLC; combination screening reference. | View MET Products |
| Related Target D (Off-target) | NTRK1. Receptor tyrosine kinase alternative in solid tumors. For cross-reactivity panels. | View NTRK1 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Gatekeeper Mutation Selectivity (V804M vs WT) | Matched Pair: Sequence-verified RET V804M and RET WT Kinase Domain proteins with >95% purity for direct IC50 comparison. |
| Cellular Resistance Model Construction | RET V804M Lentivirus: High-titer, full-length mutation expression. Enables stable Ba/F3-RET V804M line for acquired resistance studies. |
| ATP-Competitive Binding Verification | High-purity kinase domains (Theoretical MW verified by mass spec) suitable for SPR/ITC kinetic analysis. |
| Off-Target Counter-Screening | Homolog Panel: Related RTKs (NTRK1, EGFR, MET, ALK) available with identical expression standards. |
| Stable Resistance Line Generation | Lentivirus encoding RET V804M (full-length ORF); HEK293 expressed, endotoxin controlled for transduction. |
| Assay Specificity & False Positives | RET-specific siRNA set included for knockdown validation of inhibitor mechanism. |
| Kinase Activity Preservation | Recombinant active kinase domains optimized for biochemical assays (Theoretical MW, High Purity >95%). |
Live RET V804M R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic landscape for RET-driven cancers is pivoting from first-generation inhibitors to resistance-mutation capable therapies. The V804M gatekeeper substitution—located in the ATP-binding pocket—confers steric hindrance that reduces efficacy of approved agents like selpercatinib and pralsetinib. Consequently, the R&D frontier focuses on next-generation small molecules (Type II inhibitors, macrocycles) designed to accommodate the methionine substitution at position 804. As companion diagnostics for RET fusions mature, the parallel demand for V804M-specific resistance profiling is driving the market for high-fidelity mutant antigens and cellular models. Key players include Eli Lilly (LOXO-260), Turning Point/Takeda (TPX-0046), Blueprint Medicines, and Roche. Combination strategies (RET + MEK/SHP2) are also under investigation to delay resistance emergence.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Next-Gen Small Molecule TKI | Eli Lilly (LOXO-260), Turning Point (TPX-0046), Applied Biology (APS-03118), Blueprint Medicines, Roche | NSCLC (RET fusion+, V804M resistant), Medullary Thyroid Cancer | Biochemical Kinase Assay (Need high-purity RET V804M vs WT proteins for selectivity indexing) |
| Allosteric Inhibitors | Pre-clinical biotechs | Solid Tumors with acquired resistance | RET V804M Lentivirus for stable cell lines to test non-ATP competitive mechanisms |
| PROTAC Degraders | Emerging academic/industry consortia | Refractory RET-driven cancers | Cell-based assays using RET V804M full-length lentivirus to assess target engagement and degradation |
| Combination Therapy (RET + MEK/SHP2) | Academic consortia, Emerging biotech | Refractory solid tumors with acquired resistance | Synergy Assay (Need Downstream Kinase & Mutant RET Controls) |